Trump Could Soften FDA Standards - Diverse Health

Higher Education News and Jobs

Trump Could Soften FDA Standards

Email
   
        


by By John LaMattina, Contributor

They were hailed as drugs that could change the treatment of heart disease by lowering harmful LDL cholesterol (LDL-c) to unprecedented levels for adults. Yet, the sales of Amgen’s Repatha and Sanofi/Regeneron’s Praluent, known as PCSK9 inhibitors, have been disappointing low. The reason isn’t due to lack of efficacy. Indeed, combining PCSK9 inhibitors with generic statins can drop LDL-c to below 40mg/dL, almost the levels of newborns, with no major safety issues. What has limited the uptake of these drugs has been the price–listed at $14,000 a year. As a result, payers have made access difficult, requiring extensive documentation showing that patients are truly in need of such potent therapy. In fact, 88% of first-time prescriptions for patients with commercial insurance were denied access last year.

Read More

Comments

Print Friendly

Related Articles

Q&A: How Would Congress Repeal Health Care? WASHINGTON — The stakes confronting Republicans determined to dismantle President Barack Obama's health care law were evident in one recent encounter between an Ohio congressman and a constituent. “He said, ‘’Now you guys own it. Now fix it. It's ...
U.S. Prosecutor Tackles Heroin Scourge That Claimed Son HARRISBURG, Pa. — The phone at Bruce Brandler's home rang at 3:37 a.m. It was the local hospital. His 16-year-old son was there, and he was in really bad shape. A suspected heroin overdose, the nurse said. Brandler didn't believe it. Erik had h...
State Must Give Inmate $50,000-plus Medication PHILADELPHIA — A federal judge in Pennsylvania has mandated that the state should provide expensive new medication to former death-row inmate Mumia Abu-Jamal to treat his hepatitis C infection. The Philadelphia Inquirer reports Abu-Jamal sued to i...